Floatz logo

Methylphenidate

Chronic Neuropathic Pain

Unity Health TorontoSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Chronic Neuropathic Pain cohort.

Asset / SponsorPhaseRating
Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 4BB
Dfn-15
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 4BB
NEPENTHE
Nova Scotia Health Authority
Phase 4BB
Naltrexone
Emory University
Phase 4BB
FENTANYL
Cephalon
Phase 3B

View all 20 →

Same molecule, other indications

Methylphenidate is also rated in:

attention deficit-hyperactivity disorderDormant
BBB
Indicative ·
76 / 100
View asset →
ApathyDormant
BBB
Indicative ·
72 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →